Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $251.22

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $251.22.

A number of research firms have recently issued reports on IQV. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday. Truist Financial reiterated a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research report on Friday, November 1st.

IQVIA Price Performance

IQV traded down $3.05 during midday trading on Thursday, reaching $190.97. 392,563 shares of the company's stock were exchanged, compared to its average volume of 1,372,670. The firm has a market capitalization of $33.63 billion, a price-to-earnings ratio of 25.46, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a one year low of $187.62 and a one year high of $261.73. The business has a 50-day simple moving average of $199.73 and a two-hundred day simple moving average of $216.79.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA will post 10.86 EPS for the current year.

Insiders Place Their Bets

In other news, Director John G. Danhakl purchased 1,275 shares of the firm's stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently made changes to their positions in the company. Smith Group Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at $1,616,000. Simplify Asset Management Inc. increased its holdings in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. bought a new position in IQVIA during the 4th quarter worth about $941,000. Finally, Fifth Third Bancorp increased its holdings in IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.